Last edition
News about "suicidal bipolar depression"
NRx Pharmaceuticals Advances NRX-100 NDA Submission to FDA for Suicidal Depression Treatment
NRX-100 was initially granted Fast Track Designation in 2017 for use in combination with NRX-101 (D-cycloserine/lurasidone) for the treatment of suicidal bipolar depression.
Suicidal Bipolar Depression | 01/01/2025 | By Abha
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members